Ajay Subramanian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ajay Subramanian has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
- Everett J. Moding
Department of Radiation Oncology, Stanford University, Stanford, CA
63 shared publications - Neda Nemat-Gorgani
Department of Radiation Oncology, Stanford University, Stanford, California
47 shared publications - Matt van de Rijn
Department of Pathology, Stanford University, Stanford, California
31 shared publications - Timothy J. Sears
Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, USA
29 shared publications - Gregory W. Charville
Stanford University School of Medicine
27 shared publications - David S. Wang
Department of Radiology, Stanford University, Stanford, California
26 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (30) , 2941-2952
Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial
PURPOSE: Circulating tumor DNA (ctDNA) holds promise for prognostication and disease monitoring in solid tumors. However, rare and heterogenous tumors with low mutational burden like soft tissue sarcomas (STS) present a technical challenge for ctDNA analysis. We investigated the ability of personalized ctDNA analysis to predict outcomes and track response to radiotherapy and pembrolizumab in patients with localized STS. METHODS: We analyzed 313 plasma samples collected pretreatment, postradiotherapy/presurgery, and postsurgery from 106 patients treated with preoperative radiotherapy with or without perioperative pembrolizumab for high-risk, localized STS in the SU2C-SARC032 phase II randomized trial. Personalized ctDNA assays were designed to track a median of 46 somatic mutations per patient. Associations between ctDNA levels and outcomes were assessed using univariable and multivariable models adjusting for clinical risk factors. RESULTS: Personalized ctDNA profiling detected baseline ctDNA in 85% of patients. Baseline ctDNA levels correlated with tumor size, grade 3 disease, and expression of genes related to hypoxia and the cell cycle. ctDNA levels pretreatment, after radiotherapy with or without immunotherapy but before surgery, and postsurgery were strongly associated with disease-free and overall survival on univariable and multivariable analyses. Patients treated with pembrolizumab, who had significantly better disease-free survival, had a greater decrease in their ctDNA levels after neoadjuvant therapy. Finally, personalized ctDNA analysis enabled noninvasive subclone tracking and patients with multiple tumor clones detected by ctDNA analysis after surgery had inferior outcomes. CONCLUSION: Tumor-informed, personalized profiling enables sensitive ctDNA detection and quantitative monitoring in localized STS, providing independent prognostic information across the perioperative course. These findings support prospective ctDNA-guided interventional trials in STS.
- 20 October 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (30) , 2941-2952
Open AccessPersonalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial
PURPOSE: Circulating tumor DNA (ctDNA) holds promise for prognostication and disease monitoring in solid tumors. However, rare and heterogenous tumors with low mutational burden like soft tissue sarcomas (STS) present a technical challenge for ctDNA analysis. We investigated the ability of personalized ctDNA analysis to predict outcomes and track response to radiotherapy and pembrolizumab in patients with localized STS. METHODS: We analyzed 313 plasma samples collected pretreatment, postradiotherapy/presurgery, and postsurgery from 106 patients treated with preoperative radiotherapy with or without perioperative pembrolizumab for high-risk, localized STS in the SU2C-SARC032 phase II randomized trial. Personalized ctDNA assays were designed to track a median of 46 somatic mutations per patient. Associations between ctDNA levels and outcomes were assessed using univariable and multivariable models adjusting for clinical risk factors. RESULTS: Personalized ctDNA profiling detected baseline ctDNA in 85% of patients. Baseline ctDNA levels correlated with tumor size, grade 3 disease, and expression of genes related to hypoxia and the cell cycle. ctDNA levels pretreatment, after radiotherapy with or without immunotherapy but before surgery, and postsurgery were strongly associated with disease-free and overall survival on univariable and multivariable analyses. Patients treated with pembrolizumab, who had significantly better disease-free survival, had a greater decrease in their ctDNA levels after neoadjuvant therapy. Finally, personalized ctDNA analysis enabled noninvasive subclone tracking and patients with multiple tumor clones detected by ctDNA analysis after surgery had inferior outcomes. CONCLUSION: Tumor-informed, personalized profiling enables sensitive ctDNA detection and quantitative monitoring in localized STS, providing independent prognostic information across the perioperative course. These findings support prospective ctDNA-guided interventional trials in STS.
- Open Access
Predicting Neoantigen Immunogenicity from In Vivo Immune Editing
Neoantigen immunogenicity prediction is fundamental to personalized cancer vaccines, tumor-infiltrating lymphocyte (TIL) therapy, and TCR-T cell engineering. Existing computational predictors rely primarily on in-vitro correlates of peptide presentation or models trained against assay-based reactivity, and they are typically validated within a single therapeutic setting. We reasoned that the most direct evidence of neoantigen immunogenicity is longitudinal in-vivo elimination: under immune checkpoint blockade (ICB), subclones bearing recognized neoantigens are selectively depleted over time. Here, we present the Neoantigen Elimination Model (NEMo), a two-compartment (CD8 and CD4) machine learning classifier trained on the in-vivo editing (IVE) of neoantigens across serially sequenced, ICB-treated tumors. By using mechanistically inspired NeoPrecis features designed to capture determinants of immunogenicity beyond MHC binding affinity, NEMo recovered assay-confirmed immunogenic neoantigens across four independent, unseen clinical settings—pre-existing immunogenicity screening, personalized cancer vaccines, TIL therapy, and a radiotherapy±ICB ctDNA cohort—and stratified progression-free survival more strongly than ELISPOT-confirmed reactivity. The editing signal further revealed an immune-evasion architecture in which oncogenic drivers and neoantigens restricted to lost or silenced HLA alleles are systematically spared from editing. Highlights: - NEMo learns in-vivo immunoediting to prioritize immunogenic targets - NEMo outperforms existing tools across four independent clinical settings - Complete subclonal coverage and presentation integrity predict survival - Clonal oncogenic driver status and HLA damage spare neoantigens from editing
Open AccessPredicting Neoantigen Immunogenicity from In Vivo Immune Editing
Neoantigen immunogenicity prediction is fundamental to personalized cancer vaccines, tumor-infiltrating lymphocyte (TIL) therapy, and TCR-T cell engineering. Existing computational predictors rely primarily on in-vitro correlates of peptide presentation or models trained against assay-based reactivity, and they are typically validated within a single therapeutic setting. We reasoned that the most direct evidence of neoantigen immunogenicity is longitudinal in-vivo elimination: under immune checkpoint blockade (ICB), subclones bearing recognized neoantigens are selectively depleted over time. Here, we present the Neoantigen Elimination Model (NEMo), a two-compartment (CD8 and CD4) machine learning classifier trained on the in-vivo editing (IVE) of neoantigens across serially sequenced, ICB-treated tumors. By using mechanistically inspired NeoPrecis features designed to capture determinants of immunogenicity beyond MHC binding affinity, NEMo recovered assay-confirmed immunogenic neoantigens across four independent, unseen clinical settings—pre-existing immunogenicity screening, personalized cancer vaccines, TIL therapy, and a radiotherapy±ICB ctDNA cohort—and stratified progression-free survival more strongly than ELISPOT-confirmed reactivity. The editing signal further revealed an immune-evasion architecture in which oncogenic drivers and neoantigens restricted to lost or silenced HLA alleles are systematically spared from editing. Highlights: - NEMo learns in-vivo immunoediting to prioritize immunogenic targets - NEMo outperforms existing tools across four independent clinical settings - Complete subclonal coverage and presentation integrity predict survival - Clonal oncogenic driver status and HLA damage spare neoantigens from editing
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplementary Table S4 shows patient characteristics of surgical specimens from patients with sarcoma undergoing routine standard of care (n=44).
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplementary Table S4 shows patient characteristics of surgical specimens from patients with sarcoma undergoing routine standard of care (n=44).
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S10 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplementary Table S10 shows individual patient level clinical outcomes
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplementary Table S10 shows individual patient level clinical outcomes
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplemental Figure S5 shows impact of BO-112 and RT on intratumoral immune composition in human specimens.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplemental Figure S5 shows impact of BO-112 and RT on intratumoral immune composition in human specimens.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplemental Figure S1 shows focal RT using image guidance and treatment planning to target the tumor and spare local lymph node
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplemental Figure S1 shows focal RT using image guidance and treatment planning to target the tumor and spare local lymph node
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplemental Figure S6 shows intratumoral T cell evolution is facilitated by clonal replacement by less exhausted T cells, related to Figure 6.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplemental Figure S6 shows intratumoral T cell evolution is facilitated by clonal replacement by less exhausted T cells, related to Figure 6.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplemental Figure S2 shows intratumoral administration is necessary for optimal anti-tumor efficacy of BO-112
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplemental Figure S2 shows intratumoral administration is necessary for optimal anti-tumor efficacy of BO-112
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S1, S3, S6-9 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplementary Data is an excel file with supplementary tables S1, S3, and S6-S9 compiled. Supplemental Table 1 shows complete adverse events and relatedness to BO-112 or nivolumab by cohort. Supplemental Table 3 shows overall treatment emergent adverse events. Supplemental Table 6 shows key genes for annotation of myeloid clusters in scRNA-seq. Supplemental Table 7 shows top 100 differentially expressed genes for each myeloid cluster. Supplemental Table 8 shows annotation of T cell subsets by top differentially expressed genes. Supplemental Table 9 shows representativeness of Study Participants
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1, S3, S6-9 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Supplementary Data is an excel file with supplementary tables S1, S3, and S6-S9 compiled. Supplemental Table 1 shows complete adverse events and relatedness to BO-112 or nivolumab by cohort. Supplemental Table 3 shows overall treatment emergent adverse events. Supplemental Table 6 shows key genes for annotation of myeloid clusters in scRNA-seq. Supplemental Table 7 shows top 100 differentially expressed genes for each myeloid cluster. Supplemental Table 8 shows annotation of T cell subsets by top differentially expressed genes. Supplemental Table 9 shows representativeness of Study Participants